Latest News | Lupin Announces USFDA Acceptance for a Biosimilar Application
Get latest articles and stories on Latest News at LatestLY. Drug maker Lupin on Wednesday said the US health regulator has accepted its application for a biosimilar product which is used to treat cancer patients.
New Delhi, Jun 2 (PTI) Drug maker Lupin on Wednesday said the US health regulator has accepted its application for a biosimilar product which is used to treat cancer patients.
The US Food and Drug Administration (USFDA) has accepted the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim) through a filing, the Mumbai-based drug maker said in a statement.
As per IQVIA MAT December 2020 data, Pegfilgrastim has estimated annual sales of USD 3.66 billion in the US.
Pegfilgrastim is used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.
"FDA's acceptance of our BLA is a significant achievement and demonstrates our commitment to delivering products which increase access in areas of substantial medical need. This BLA expands our oncology portfolio, an area of increasing focus for Lupin. We look forward to the opportunity to bring affordable biologic options to patients and increasing access to this important treatment," Lupin CEO Vinita Gupta said.
The pegfilgrastim filing is the company's first biosimilar filing in the US and is a milestone in the drug maker's research and innovation journey, Lupin MD Nilesh Gupta noted.
"Biosimilars is a key part of our growth strategy and we are proud of the world-class achievements of our group," he added.
Shares of the company were trading 2.68 per cent up at Rs 1,41.05 apiece on the BSE. -- Munish Shekhavat Senior Chief Correspondent Economic Bureau Press Trust of India (PTI) 4, Parliament Street New Delhi, 110001 Tel 41394549; Fax 23718714 Mob 09999456088 Email: HYPERLINK "mailto:munish.shekhavat@gmail.com" nmunish.shekhavat@gmail.com, HYPERLINK "mailto:munish@pti.in" nmunish.shekhavat@pti.in
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)